PubRank

G C White

Author PubWeight™ 107.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990 5.28
2 A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989 4.04
3 Occupations of fathers of children dying from neoplasms. J Epidemiol Community Health 1981 3.25
4 HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997 1.95
5 A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A 1987 1.87
6 SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem 1998 1.77
7 Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost 2003 1.74
8 Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998 1.69
9 Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988 1.63
10 Superior mesenteric vein thrombosis with radiologically occult cause: a retrospective study of 43 cases. AJR Am J Roentgenol 2001 1.61
11 Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000 1.44
12 PCB intake and the growth of waterfowl: multivariate analyses based on a reparameterized Richards sigmoid model. Growth 1986 1.40
13 The partial thromboplastin time. J Thromb Haemost 2014 1.39
14 Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001 1.35
15 The genomic organization of platelet glycoprotein IIIa. J Biol Chem 1990 1.29
16 Distribution of survival times of 12,000 head and neck cancer patients who died with their disease. Br J Cancer 1976 1.17
17 Cancer mortality and saccharin consumption in diabetics. Br J Prev Soc Med 1976 1.14
18 Thrombolamban, the 22-kDa platelet substrate of cyclic AMP-dependent protein kinase, is immunologically homologous with the Ras family of GTP-binding proteins. Proc Natl Acad Sci U S A 1990 1.14
19 rap1B, a cAMP-dependent protein kinase substrate, associates with the platelet cytoskeleton. J Biol Chem 1990 1.13
20 Mortality of wives of men dying with cancer of the penis. Br J Cancer 1980 1.08
21 The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001 1.08
22 B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 2005 1.07
23 Calcium-dependent proteins in platelets: response of calcium-activated protease in normal and thrombasthenic platelets to aggregating agents. Biochim Biophys Acta 1980 1.04
24 Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation. Studies with activated and inhibitory beta3 cytoplasmic domain mutants. J Biol Chem 1997 1.04
25 Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci U S A 1999 0.99
26 Transmission of human immunodeficiency virus to sexual partners of hemophiliacs. Am J Hematol 1988 0.97
27 Incorporation of Rap 1b into the platelet cytoskeleton is dependent on thrombin activation and extracellular calcium. J Biol Chem 1994 0.97
28 Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2004 0.96
29 The effects of trifluoperazine, an inhibitor of calmodulin, on platelet function. Thromb Res 1980 0.96
30 Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 1992 0.95
31 ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999 0.93
32 Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1. J Biol Chem 1996 0.93
33 Wound infection rates after invasive procedures in HIV-1 seropositive versus HIV-1 seronegative hemophiliacs. Ann Surg 1990 0.93
34 von Willebrand factor multimeric levels and patterns in patients with severe preeclampsia. Obstet Gynecol 1990 0.91
35 Antithrombin-III transfusion in disseminated intravascular coagulation. Lancet 1978 0.90
36 Physiological traits associated with success of Candida albicans strains as commensal colonizers and pathogens. J Clin Microbiol 1995 0.89
37 Increasing incidence of cryptococcosis in the United Kingdom. J Infect 1993 0.89
38 Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992 0.89
39 Treatment of anti-factor VIII antibodies. Thromb Haemost 1977 0.89
40 Structure-function relationships in the interaction of alpha-thrombin with blood platelets. J Biol Chem 1977 0.89
41 Rap1b is critical for glycoprotein VI-mediated but not ADP receptor-mediated alpha2beta1 activation. J Thromb Haemost 2009 0.88
42 The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med 1988 0.88
43 Partial purification and characterization of thrombolamban, a 22,000 dalton cAMP-dependent protein kinase substrate in platelets. Biochem Biophys Res Commun 1987 0.88
44 Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 2000 0.88
45 Platelet factor 4 enhances fibrin fiber polymerization. Thromb Res 1987 0.87
46 HTLV-III seroconversion associated with heat-treated factor VIII concentrate. Lancet 1986 0.87
47 Thrombin binding to thrombasthenic platelets. J Lab Clin Med 1978 0.87
48 Chronic hepatitis in patients with hemophilia A: histologic studies in patients with intermittently abnormal liver function tests. Blood 1982 0.87
49 Breeding in high-elevation habitat results in shift to slower life-history strategy within a single species. J Anim Ecol 2008 0.87
50 Evidence that platelet and skeletal sarcoplasmic reticulum Ca2+-ATPase are structurally distinct. J Biol Chem 1985 0.86
51 Heterogeneity of membrane surface proteins in Glanzmann's thrombasthenia. Blood 1981 0.86
52 Immunoglobulin D myeloma and amyloidosis: immunochemical and structural studies of Bence Jones and amyloid fibrillar proteins. Blood 1975 0.86
53 Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol 1998 0.85
54 HTLV-III exposure during cardiopulmonary resuscitation. N Engl J Med 1985 0.85
55 Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case. Blood 1983 0.85
56 Orthopaedic procedures and prognosis in hemophilic patients who are seropositive for human immunodeficiency virus. J Bone Joint Surg Am 1990 0.85
57 An investigation of functional similarities between the sarcoplasmic reticulum and platelet calcium-dependent adenosinetriphosphatases with the inhibitors quercetin and calmidazolium. Biochemistry 1987 0.85
58 Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988 0.84
59 Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol 1996 0.84
60 Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000 0.83
61 Heparin cofactor activities in a family with hereditary antithrombin III deficiency: evidence for a second heparin cofactor in human plasma. Blood 1983 0.83
62 Hemophilia, hepatitis, and the acquired immunodeficiency syndrome. Ann Intern Med 1983 0.83
63 Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977 0.82
64 Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983 0.82
65 Estimation and comparison of parameters in stochastic growth models for barn owls. Growth 1980 0.82
66 Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999 0.81
67 Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice. J Thromb Haemost 2003 0.81
68 Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs. Am J Med 1991 0.81
69 Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. Nouv Rev Fr Hematol 1986 0.81
70 cAMP-dependent protein kinase substrates in platelets. Evidence that thrombolamban, a 22,000 dalton substrate, and the Ca++-ATPase are not associated proteins. Biochem Biophys Res Commun 1989 0.80
71 Intracellular function in rehydrated lyophilized platelets. Br J Haematol 2000 0.80
72 AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996 0.80
73 Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hematol 1990 0.80
74 Carcinoma of penis and cervix. Lancet 1980 0.80
75 Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J Thromb Haemost 2003 0.80
76 Medical complications of hemophilia. South Med J 1980 0.80
77 Colonoscopic polypectomy in Glanzmann's thrombasthenia. Gastrointest Endosc 1983 0.79
78 The effect of phenothiazine and non-phenothiazine inhibitors of calmodulin on platelet calcium fluxes. Biochem Biophys Res Commun 1982 0.79
79 Effect of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine on calcium fluxes by human platelet microsomes. Biochem Biophys Res Commun 1984 0.79
80 Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis 1995 0.79
81 Structure-function relations in platelet-thrombin reactions. Inhibition of platelet-thrombin interactions by lysine modification. J Biol Chem 1981 0.79
82 Bladder cancer in rubber workers. Do screening and doctors' awareness distort the statistics? Lancet 1976 0.79
83 Hydrolysis of human platelet membrane glycoproteins with a Serratia marcescens metalloprotease: effect on response to thrombin and von Willebrand factor. Proc Natl Acad Sci U S A 1982 0.79
84 Ozone inhibits prostacyclin synthesis in pulmonary endothelium. Prostaglandins 1985 0.78
85 Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationship to CD4 counts, and predictive value. Blood 1993 0.78
86 Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Am J Hematol 1995 0.77
87 Platelet calcium-dependent proteins: identification and localization of the calcium-dependent regulator, calmodulin, in platelets. Am J Hematol 1981 0.77
88 Low incidence of thrombocytopenia with porcine mucosal heparin. A prospective multicenter study. Arch Intern Med 1989 0.77
89 Hepatocellular carcinoma in hemophilia. Am J Hematol 1991 0.77
90 Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002 0.77
91 Prolonged neonatal alloimmune thrombocytopenic purpura associated with anti-Bak(a). Two cases in siblings. Am J Perinatol 1987 0.77
92 Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 1990 0.77
93 The localization of the cAMP-dependent protein kinase phosphorylation site in the platelet rat protein, rap 1B. FEBS Lett 1991 0.77
94 Failure of sexual activity to reinforce female rats. J Comp Physiol Psychol 1968 0.77
95 Factor VIII inhibitors: a clinical overview. Am J Hematol 1982 0.76
96 High resolution electrophoretic analysis of human fibrinogen and its crosslinked intermediates. Thromb Haemost 1983 0.76
97 Kinetic evidence that arachidonate-induced calcium efflux from platelet microsomes involves a carrier-type ionophoric mechanism. Biochim Biophys Acta 1990 0.76
98 Urinary cortisol and urea nitrogen responses in irreversibly undernourished mule deer fawns. J Wildl Dis 1991 0.76
99 Morphological study of early phases of platelet adhesion to foreign surfaces: effect of calcium. Ann N Y Acad Sci 1983 0.76
100 Giant platelet disorder in a patient with type 2B von Willebrand's disease. Am J Hematol 1998 0.76
101 Expression and function of calcium binding domain chimeras of the integrins alpha(IIb) and alpha(5). J Biol Chem 2000 0.76
102 Risk of HIV infection and AIDS in women and girls with coagulation disorders. AIDS 1994 0.76
103 Rainsplash as a mechanism for soil contamination of plant surfaces. Health Phys 1984 0.76
104 The identification of sarcoplasmic reticulum terminal cisternae proteins in platelets. Biochem J 1989 0.75
105 Gene therapy for hemophilia? J Thromb Haemost 2005 0.75
106 High affinity binding of thrombin to platelets. Inhibition by tetranitromethane and heparin. Biochem Biophys Res Commun 1977 0.75
107 Glycoprotein V hydrolysis by thrombin. Lack of correlation with secretion. Thromb Res 1985 0.75
108 The effect of ambient storage on platelet membrane structure and response to thrombin. Transfusion 1979 0.75
109 Estimation and testing of parameters in Richards growth model for western grebes. Growth 1977 0.75
110 The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. Instr Course Lect 1983 0.75
111 Disturbance of a low-level waste burial site cover by pocket gophers. Health Phys 1982 0.75
112 Valproic acid: a new antiepileptic drug with potential side effects of dental concern. J Am Dent Assoc 1979 0.75
113 Effect of active site-modified thrombin on the hydrolysis of platelet-associated glycoprotein V by native thrombin. Blood 1985 0.75
114 Effective sedation and local anaesthesia for high risk cardiac patients. J Can Dent Assoc (Tor) 1972 0.75
115 Sigmoid growth analyses of wood ducks: the effects of sex, dietary protein and cadmium on parameters of the Richards model. Growth 1986 0.75
116 Phenotypic modification of the reactivity in human serum of Escherichia coli K1 isolates. Zentralbl Bakteriol Mikrobiol Hyg A 1984 0.75
117 A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A. Haemophilia 1997 0.75
118 The hemostatic mechanism: mechanistic, diagnostic and therapeutic considerations. N C Dent J 1975 0.75
119 Platelet-thrombin interactions as assessed by affinity chromatography. Thromb Res 1976 0.75
120 Hydrophobic affinity chromatography of human thrombin. Arch Biochem Biophys 1993 0.75
121 Cherubism: report of case. J Oral Surg 1974 0.75
122 Simulation model of tritium kinetics in a freshwater marsh. Health Phys 1978 0.75
123 The effect of platelet inhibitors on glycoprotein V hydrolysis by thrombin. Thromb Res 1984 0.75
124 Tendency to serious sequelae of infection with the human immunodeficiency virus in sibships with hemophilia. Arch Intern Med 1989 0.75
125 Soil plutonium and cesium in stream channels and banks of Los Alamos liquid effluent-receiving areas. Health Phys 1982 0.75
126 Treatment of the hemophilias. Curr Opin Hematol 1995 0.75
127 Factor IX activator content of normal and factor XI deficient serum. Thromb Res 1978 0.75
128 Prevalence of hepatitis A antibodies in hemophiliacs: preliminary results from the Southeastern Delta Hepatitis Study. Vox Sang 1994 0.75
129 Glanzmann's thrombasthenia. Report of two oral surgical cases using a new microfibrillar collagen preparation and EACA for hemostasis. Oral Surg Oral Med Oral Pathol 1979 0.75
130 Cirrhosis, variceal bleeding, and distal splenorenal shunt in hemophilia A. South Med J 1982 0.75
131 Procreation and HIV. Lancet 1993 0.75
132 Sigmoid growth and the assessment of hormesis: a case for caution. Health Phys 1987 0.75
133 Synovial chondromatosis of the TMJ: case report and review of literature. J Can Dent Assoc 1989 0.75
134 Disinfection practices in the San Francisco Bay area. J Water Pollut Control Fed 1974 0.75
135 The development of a high-order Taylor expansion solution to the chemical rate equation for the simulation of complex biochemical systems. Comput Appl Biosci 1990 0.75
136 An evaluation of soil sampling for 137Cs using various field-sampling volumes. Health Phys 1983 0.75
137 Effect of rototilling on the distribution of cesium-137 in Trinity Site soil. Health Phys 1981 0.75
138 Prothrombin complex concentrates: preparation, properties, and clinical uses. Curr Top Hematol 1979 0.75
139 A preliminary model of DDT kinetics in an old-field ecosystem. Environ Qual Saf Suppl 1975 0.75
140 Affinity chromatography of platelets on immobilized thrombin: retention of catalytic activity by platelet-bound thrombin. Thromb Res 1992 0.75
141 Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody. JAMA 1984 0.75
142 Cranial pseudotumour in haemophilia. Haemophilia 2004 0.75
143 Biological elimination rates of radioisotopes by mallards contaminated at a liquid radioactive waste disposal area. Health Phys 1983 0.75
144 Hepatitis delta infection among multiply-transfused hemophiliacs. Prog Clin Biol Res 1991 0.75
145 Alterations in platelet membrane structure and function during storage at ambient temperature. Prog Clin Biol Res 1978 0.75